Should I Buy MDWD? MDWD 2026 Analysis

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

17.770

1 Day change

-3.56%

52 Week Range

22.500

Analysis Updated At

2026/01/26

MediWound Ltd (MDWD) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive long-term growth potential with increased manufacturing capacity expected by mid-2026 and a raised price target from analysts, the current technical indicators and financial performance do not support an immediate buy decision. The stock's technical trend is neutral to bearish, and the company's financials show declining net income and EPS despite revenue growth. Additionally, there are no significant trading trends, news catalysts, or proprietary trading signals to suggest an immediate opportunity.

Technical Analysis

The stock's MACD is below 0 and negatively contracting, indicating a bearish momentum. RSI is neutral at 54.427, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 17.595, with resistance at 18.76 and support at 16.43. Overall, the technical indicators suggest a neutral to bearish trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The options data indicates a bullish sentiment with a low put-call ratio for volume (0.24), suggesting more call buying activity. However, the open interest put-call ratio of 0.67 reflects a more balanced sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Revenue grew 24.66% YoY in Q3 2025.

Neutral/Negative Catalysts

No recent news or significant trading trends from hedge funds, insiders, or Congress. Technical indicators are neutral to bearish, and the stock shows a potential for negative returns over the next month (-6.88%).

Financial Performance

In Q3 2025, revenue increased by 24.66% YoY to $5,429,000, but net income dropped to -$2,652,000 (-74.21% YoY), and EPS fell to -0.24 (-75.51% YoY). Gross margin improved slightly to 16.5% (+6.11% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating and raised the price target to $36 from $31, citing long-term growth potential due to increased manufacturing capacity expected by mid-2026.

6 Analyst Rating

Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30 USD with a low forecast of 25 USD and a high forecast of 36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 18.420

Low

Averages

High

Current: 18.420

Low

Averages

High

H.C. Wainwright

Buy

maintain

$31 -> $36

AI Analysis

2025-11-21

Reason

H.C. Wainwright

Price Target

$31 -> $36

AI Analysis

2025-11-21

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.

Oppenheimer

Outperform

downgrade

$36 -> $34

2025-06-02

Reason

Oppenheimer

Price Target

$36 -> $34

2025-06-02

downgrade

Outperform

Reason

Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDWD

Unlock Now

MDWD Should I Buy

MDWD Should I Buy

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch